Breaking News Instant updates and real-time market news.

SSYS

Stratasys

$20.79

-0.44 (-2.07%)

, DDD

3D Systems

$14.26

-0.56 (-3.78%)

13:50
10/16/16
10/16
13:50
10/16/16
13:50

Unpopular names in 3D printing, chips could offer opportunity, Barron's says

Stratasys (SSYS) and 3D Systems (DDD) "have the same problems," but the former is sharply underperforming the latter, leading Barron's to contend in a 'Technology Trader' column that it "may be worth" buying Stratasys. The publication argues that the 3D printing sector, which also includes Voxeljet (VJET) and ExOne (XONE), could be ripe for consolidation under buyouts by a Jabil Circuit (JBL), Flex (FLEX) or Applied Materials (AMAT). Beyond the 3D printing market, Barron's also highlights valuation discrepancies in semiconductors and components, where unpopular Skyworks (SWKS), Qorvo (QRVO), Integrated Device Technology (IDTI), Universal Display (OLED) could become more favored trades. Reference Link

SSYS

Stratasys

$20.79

-0.44 (-2.07%)

DDD

3D Systems

$14.26

-0.56 (-3.78%)

VJET

voxeljet

$4.29

-0.09 (-2.05%)

XONE

ExOne

$13.22

-0.32 (-2.36%)

JBL

Jabil Circuit

$21.26

-0.05 (-0.23%)

FLEX

Flex

$13.71

0.08 (0.59%)

AMAT

Applied Materials

$28.07

0.21 (0.75%)

SWKS

Skyworks

$77.63

0.22 (0.28%)

QRVO

Qorvo

$53.00

0.09 (0.17%)

IDTI

Integrated Device

$19.79

0.06 (0.30%)

OLED

Universal Display

$49.22

-0.54 (-1.09%)

  • 19

    Oct

  • 27

    Oct

  • 31

    Oct

  • 03

    Nov

  • 03

    Nov

  • 03

    Nov

  • 14

    Nov

  • 15

    Nov

SSYS Stratasys
$20.79

-0.44 (-2.07%)

09/15/16
KEYB
09/15/16
NO CHANGE
KEYB
3D printer, robot companies can benefit from manufacturing trend, says KeyBanc
After attending a manufacturing technology show, KeyBanc expects "short-cycle" OEMs to "remain focused on cost savings and efficiency improvement." 3D printing and "collaborative robot" systems can help meet this goal, according to the firm. The trend is positive for 3D Systems (DDD), Stratasys (SSYS), Materialise (MTLS), and Teradyne (TER), according to the firm. It keeps an Overweight rating on Materialise and Sector Weight ratings on the remaining companies named.
10/03/16
FBRC
10/03/16
INITIATION
Target $29
FBRC
Outperform
Stratasys coverage transferred with an Outperform at FBR Capital
FBR Capital transferred coverage on Stratasys to analyst Christopher Van Horn who has an Outperform rating and a $29 price target on shares.
10/13/16
PIPR
10/13/16
NO CHANGE
PIPR
After survey, Piper cautious on 3D printing stocks into earnings
Piper Jaffray analyst Troy Jensen says his firm's 3D printing survey for Q3 indicates system demand "remained challenged" in the quarter. The below plan responses "significantly" outnumbered resellers indicating above plan, Jensen tells investors in a research note. The September quarter survey had the lowest percentage of above plan responses in the history of Piper's survey, the analyst points out. Jensen advises caution on 3D printing stocks into the Q3 earnings season. The analyst sees limited downside for Stratasys (SSYS) shares and more downside for 3D Systems (DDD) given its "internal issues and premium valuation."
08/24/16
DBAB
08/24/16
NO CHANGE
DBAB
Hold
Stratasys technology interesting, but industry still paused, says Deutsche Bank
Deutsche Bank analyst Sherri Scribner said she found the new vertical 3D printing technology introduced by Stratasys at its media and investor event yesterday to be interesting, noting that it is said to allow the printing of larger or even "infinite" size objects and increase printing speed. However, the 3D printing industry remains paused and the company offered no new financial information or timeline for the release of its new products, said Scribner, who keeps a Hold rating on Stratasys shares.
DDD 3D Systems
$14.26

-0.56 (-3.78%)

10/03/16
10/03/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. 3D Systems (DDD) coverage transferred with a Market Perform at FBR Capital. 2. Carnival (CCL) initiated with a Buy at HSBC. 3. GoDaddy (GDDY) initiated with a Buy at Summit Redstone. 4. Versum Materials (VSM) initiated with a Buy at Seaport Global. 5. ExOne (XONE) coverage transferred with an Outperform at FBR Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/16
FBRC
10/03/16
INITIATION
Target $18
FBRC
Market Perform
3D Systems coverage transferred with a Market Perform at FBR Capital
FBR Capital transferred coverage on 3D Systems to analyst Christopher Van Horn who has a Market Perform rating and a $18 price target on shares.
VJET voxeljet
$4.29

-0.09 (-2.05%)

05/20/16
IMPC
05/20/16
NO CHANGE
IMPC
voxeljet rating withdrawn at Imperial Capital
Imperial Capital analyst Saliq Khan withdrew his rating on voxeljet citing the high volatility associated with the shares.
08/15/16
PIPR
08/15/16
NO CHANGE
Target $5.7
PIPR
Overweight
voxeljet pullback offers good value opportunity, says Piper Jaffray
Piper Jaffray analyst Troy Jensen says the post-earnings selloff in shares of voxeljet provides a good value buying opportunity. The company's sales in Q2 were affected by a push out in system orders from key customers within Oil & Gas and Energy industries, Jensen tells investors in a research note. He lowered his price target for the shares to $5.70 from $7.30 but keeps an Overweight rating on voxeljet. Jensen remains positive on the company's 12 month outlook and pipeline for new products.
08/12/16
COWN
08/12/16
NO CHANGE
Target $4.5
COWN
Market Perform
voxeljet price target lowered to $4.50 from $6.00 at Cowen
Cowen analyst Robert Stone cut his estimates for voxeljet and lowered his price target on shares to $4.50 from $6.00, citing the company's wider than expected net loss, lower than expected revenue and reduced guidance. The firm keeps a Market Perform rating on the stock.
XONE ExOne
$13.22

-0.32 (-2.36%)

05/24/16
FBRC
05/24/16
INITIATION
Target $14
FBRC
Outperform
ExOne initiated with an Outperform at FBR Capital
Target $14.
06/01/16
PACS
06/01/16
NO CHANGE
PACS
Survey of industrial companies upbeat for 3D printing sector, says Pacific Crest
After surveying a number of industrial companies it covers, Pacific Crest says that over 50% of the companies it surveyed " plan to invest substantially in 3D printing capabilities," while "many companies" expect 3D printing to be used for production within five years. Moreover, "most companies didn't agree that 3D printing was overhyped," the firm stated. However, the firm adds that survey participants expressed "healthy skepticism" about the technology. Pacific Crest says that the survey results were "slightly positive" for the 3D printing names it covers- 3D Systems (DDD), Stratasys (SSYS), Materialise (MTLS), Proto Labs (PRLB), and ExOne (XONE). The firm continues to identify Materialise as its favorite name in the sector over the near-term.
10/03/16
FBRC
10/03/16
INITIATION
Target $18
FBRC
Outperform
ExOne coverage transferred with an Outperform at FBR Capital
FBR Capital transferred coverage on ExOne to analyst Christopher Van Horn who has an Outperform rating and a $18 price target on shares.
JBL Jabil Circuit
$21.26

-0.05 (-0.23%)

09/22/16
NEED
09/22/16
DOWNGRADE
NEED
Hold
Jabil Circuit downgraded to Hold from Buy at Needham
09/22/16
STPT
09/22/16
DOWNGRADE
STPT
Hold
Jabil Circuit downgraded to Hold from Buy at Standpoint Research
09/22/16
09/22/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. CBS (CBS) downgraded to Market Perform from Outperform at Telsey Advisory with analyst Tom Eagan saying that CBS will probably merge with Viacom (VIA, VIAB). 2. Jabil Circuit (JBL) downgraded to Hold from Buy at Needham with analyst Sean Hannan saying that 2017 will unlikely be a "robust year." 3. Pearson (PSO) downgraded to Neutral from Outperform at Exane BNP Paribas. 4. Syntel (SYNT) downgraded to Market Perform from Outperform at Barrington with analyst Vincent Colicchio saying he's "increasingly concerned that the challenging environment will continue to negatively impact the company's business." 5. FMC Technologies (FTI) downgraded to Neutral from Accumulate at Seaport Global wit analyst Mark Brown saying upstream customers have "little appetite" for deepwater development spending. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/22/16
09/22/16
DOWNGRADE

Hold
Jabil Circuit downgraded to Hold at Needham
As previously reported, Needham analyst Sean Hannan downgraded Jabil Circuit (JBL) to Hold from Buy after the company reported quarterly results, saying that 2017 will unlikely be a "robust year." While the analyst acknowledged that Q4 results were healthy and relationship with Apple (AAPL) seems consistent, he says the magnitude of customer sell-through creates the big question for 2017 growth.
FLEX Flex
$13.71

0.08 (0.59%)

10/05/16
10/05/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. UBS (UBS) upgraded to Sector Perform from Underperform at RBC Capital with analyst Fiona Swaffield saying she sees a dividend reduction as unlikely and believes expectations for the bank's Wealth Management business are now lower. 2. Parker-Hannifin (PH) upgraded to Buy from Hold at Stifel with analyst Nathan Jones saying distributors expect to see revenue growth declining 2% in the second quarter of fiscal 2017 which he believes should be enough for Parker to see its first positive year-over-year revenue comp company wide in six quarters. 3. Flex (FLEX) upgraded to Conviction Buy from Buy at Goldman with analyst Mark Delaney saying it is positioned to benefit from entry into new markets and valuation looks attractive. 4. KBR (KBR) upgraded to Accumulate from Hold at Johnson Rice with analyst Martin Malloy citing the recent pullback in shares and said the stock multiple should trend higher given the shift in business mix to more low-risk, cost reimbursement revenues. 5. Plains All American (PAA) upgraded to Outperform from Market Perform at Wells Fargo. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/05/16
GSCO
10/05/16
UPGRADE
Target $16
GSCO
Conviction Buy
Flex upgraded to Conviction Buy from Buy at Goldman
Goldman analyst Mark Delaney added Flex to the Conviction Buy List and maintained its $16 price target saying it is positioned to benefit from entry into new markets and valuation looks attractive. Delaney said new markets could nearly double Flex's TAM in soft goods manufacturing in the long-term, and Nike could develop into a top customers and drive margin expansion. Further, the company has an improving mix and shares trade at a discount to peers, the analyst wrote in a research note.
05/24/16
STPT
05/24/16
DOWNGRADE
STPT
Hold
Flex downgraded to Hold from Buy at Standpoint Research
09/20/16
GSCO
09/20/16
UPGRADE
Target $16
GSCO
Buy
Flex upgraded to Buy from Neutral at Goldman
Goldman analyst Mark Delaney upgraded Flex (FLEX) to Buy and raised its price target to $16 from $13. The analyst said Flex is entering the footwear manufacturing market with its expanded partnership with Nike (NKE), nearly doubling its addressable market. Further the company has diversified its end market exposure and is now less reliant on traditional tech markets like handsets, the analyst wrote. Delaney adds that Flex trades at a discount to the group despite better growth and diversification.
AMAT Applied Materials
$28.07

0.21 (0.75%)

10/05/16
RBCM
10/05/16
NO CHANGE
RBCM
Micron report reads positively for Applied Materials, Lam, says RBC Capital
Following Micron's (MU) quarterly report and guidance, RBC Capital Amit Daryanani said he sees positive read-through from the report for Applied Materials (AMAT), Lam Research (LRCX), ASML (ASML), Western Digital (WDC) and Intel (INTC). Micron management expects capex spending of $4.8B-$5.2B for FY17, noted Daryanani, who believes continued 3D NAND spending will benefit Applied and Lam the most.
09/19/16
SBSH
09/19/16
NO CHANGE
Target $37
SBSH
Buy
Applied Materials price target raised to $37 from $32 at Citi
Citi analyst Atif Malik raised his price target for Applied Materials to $37 ahead of the company's investor day on September 21. The analyst sees multiple expansion with "spend drivers like 3D NAND, China, and OLED" remaining "in early innings," Malik tells investors in a research note. He reiterates a Buy rating on Applied Materials.
10/12/16
PACS
10/12/16
DOWNGRADE
PACS
Sector Weight
Nanometrics, Lam Research downgraded to Sector Weight at Pacific Crest
Pacific Crest analyst Weston Twigg downgraded both Nanometrics (NANO) and Lam Research (LRCX) to Sector Weight from Overweight saying 3D NAND equipment demand is likely to peak in 2017. The analyst expects order declines and limited demand growth for semiconductor equipment names, which he sees limiting share upside. Twigg keeps Overweight ratings on Applied Materials (AMAT), MKS Instruments (MKSI) and Entegris (ENTG) for their longer term potential.
10/04/16
GSCO
10/04/16
DOWNGRADE
GSCO
Buy
Applied Materials downgraded to Buy from Conviction Buy at Goldman
Goldman analyst Toshiya Hari removed Applied Materials from the Conviction Buy List due to relative outperformance. The analyst maintains a Buy rating and $33 price target on shares given strong industry fundamentals, market share gains, opportunity in mobile display, a strong management team, and upside to Street estimates.
SWKS Skyworks
$77.63

0.22 (0.28%)

09/15/16
SPHN
09/15/16
NO CHANGE
SPHN
Stephens remains a buyer of Qorvo, Skyworks
Stephens analyst Harsh Kumar believes this is an attractive entry point for RF semiconductor names such as Qorvo (QRVO) and Skyworks (SWKS) going into earnings. The analyst thinks both are well positioned for upside in the September quarter. Further, he believes the build for Apple's (AAPL) iPhone 7 is likely to be rather conservative, which sets up well for growth in the December quarter as well. Kumar has an Overweight rating on both Qorvo and Skyworks' shares.
09/19/16
KEYB
09/19/16
NO CHANGE
KEYB
Broadcom, Skyworks, Cirrus Logic have iPhone content gains, says KeyBanc
KeyBanc says that reports on iPhone teardowns indicate that Broadcom's (AVGO) iPhone content rose 25%-30%, while Skyworks' (SWKS) content rose 15%-20% and Cirrus' (CRUS) jumped 70%. The firm keeps an Overweight rating on Broadcom, and Sector Weight ratings on Skyworks and Cirrus.
09/15/16
OPCO
09/15/16
NO CHANGE
OPCO
Outperform
Skyworks remains 'misunderstood, mispriced,' says Oppenheimer
Oppenheimer analyst Rick Schafer says he is "incrementally impressed" with Skyworks' (SWKS) position in its core mobile and broad markets/IoT segments after meeting with the company's management. The analyst expects above seasonal quarter over quarter revenue growth in the Q1 as content gains in Apple's (AAPL) iPhone 7 take root and a return to year over year growth in Q2. Schafer believes Skyworks remains "misunderstood/mispriced" and notes he likes the long-term set up. He has an Outperform rating on Skyworks' shares.
10/04/16
CHAR
10/04/16
UPGRADE
CHAR
Buy
Skyworks upgraded to Buy from Market Perform at Charter Equity
QRVO Qorvo
$53.00

0.09 (0.17%)

09/07/16
OTRG
09/07/16
NO CHANGE
OTRG
Qorvo may lose ultra-high band PA in iPhne 7, says OTR Global
07/11/16
BOFA
07/11/16
NO CHANGE
BOFA
Buy Broadcom, Qorvo and Skyworks, says BofA/Merrill
BofA/Merrill analyst Vivek Arya sees 25%-40% upside for Broadcom (BRCM),Qorvo (QRVO), and Skyworks (SWKS). The analyst said iPhone 6S weakness is largely over, iPhone 7 muted unit demand is reflected in estimates, and 2017's iPhone model with potential new AMOLED screen could be a material catalyst. Arya expects growth to re-accelerate and continues to see content growth at the high-end.
08/03/16
NEED
08/03/16
NO CHANGE
Target $63
NEED
Buy
Qorvo price target raised to $63 from $53 at Needham
Needham analyst N. Quinn Bolton raised his price target for Qorvo to $63 from $53 after the company reported better than expected Q1 results and provided impressive top line guidance for Q2. The analyst is encouraged by the company's revenue performance and plans to address its margin issues over the next quarters, which should drive multiple expansion. Bolton reiterates a Buy rating on the shares.
IDTI Integrated Device
$19.79

0.06 (0.30%)

08/02/16
BOFA
08/02/16
NO CHANGE
BOFA
Integrated Device's growth expected to return in 2017, says BofA/Merrill
09/28/16
ROTH
09/28/16
INITIATION
Target $26
ROTH
Buy
Integrated Device initiated with a Buy at Roth Capital
Roth Capital analyst Suji Desilva initiated Integrated Device with a Buy and a $26 price target. Desilva believes Integrated Device represents a differentiated investment opportunity in high margin mixed-signal analog and power semiconductor capabilities that are being applied to a diversified base of end markets customers.
08/18/16
JPMS
08/18/16
INITIATION
Target $26
JPMS
Overweight
Integrated Device initiated with an Overweight at JPMorgan
JPMorgan analyst Harlan Sur started Integrated Device Technology with an Overweight rating and $26 price target.
08/02/16
NEED
08/02/16
NO CHANGE
Target $25
NEED
Buy
Integrated Device should be bought on weakness, says Needham
Needham analyst N. Quinn Bolton says Integrated Device's quarterly results were overshadowed by lower-than-expected guidance reflecting Huawei's decision to internally source the SRIO switch. The analyst says that while the Huawei decision is "disappointing," he is encouraged by continued strength in Integrated Device's analog/mixed signal products. Further, Bolton believes investors are over-reacting to the news and recommends using the weakness as an opportunity to accumulate shares. The analyst reiterates a Buy rating on Integrated Device's stock and lowered his price target on the shares to $25 from $27.
OLED Universal Display
$49.22

-0.54 (-1.09%)

10/11/16
COWN
10/11/16
NO CHANGE
Target $75
COWN
Outperform
Universal Display shares oversold, buy weakness, says Cowen
Cowen said Universal Display shares are oversold on Samsung ending Note 7 production. Analyst Robert Stone said the news may reduce Samsung short-term emitter purchases, but expects continued share gains vs. LCD. The analyst said many other Samsung devices use AMOLED displays, other external customers have been supply constrained, and the Q4 license payment is fixed. Stone recommend buying Universal Display on weakness and reiterates his Outperform rating and $75 price target.
09/30/16
COWN
09/30/16
NO CHANGE
COWN
Universal Display weakness unwarranted, says Cowen
Cowen said Universal Display weakness related to reports Apple (AAPL) is in talks with Sharp as an additional supplier of OLED screens is overdone and a buying opportunity. The firm's analyst said Sharp would have to go through Universal Display to get phosphorescent organic light-emitting diodes which is essential to make a commercial screen.
09/23/16
ADAM
09/23/16
INITIATION
Target $51
ADAM
Hold
Universal Display coverage assumed with a Hold at Canaccord
Target $51.
08/05/16
NEED
08/05/16
DOWNGRADE
NEED
Hold
Universal Display downgraded to Hold at Needham
As previously reported, Needham analyst James Ricchiuti downgraded Universal Display to Hold from Buy after the company's Q2 results came in modestly below expectations and management reduced the second half of the year revenue outlook, citing expectations of a less favorable mix of emitter revenue and lower than expected royalty revenues. While the analyst believes these are temporary issues, he says these headwinds could carry well into 2017.

TODAY'S FREE FLY STORIES

CELG

Celgene

$117.63

-1.24 (-1.04%)

22:25
12/04/16
12/04
22:25
12/04/16
22:25
Conference/Events
Celgene to hold an analyst and investor event »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

AAPL

Apple

$109.90

0.41 (0.37%)

, ALNY

Alnylam

$41.57

-0.01 (-0.02%)

21:48
12/04/16
12/04
21:48
12/04/16
21:48
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

AAPL

Apple

$109.90

0.41 (0.37%)

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

BLCM

Bellicum Pharmaceuticals

$18.72

1.74 (10.25%)

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

CELG

Celgene

$117.63

-1.24 (-1.04%)

UTX

United Technologies

$108.22

0.74 (0.69%)

RXN

Rexnord

$20.27

-0.72 (-3.43%)

ETP

Energy Transfer Partners

$34.38

1.16 (3.49%)

EVC

Entravision

TJX

TJX

$77.10

-0.57 (-0.73%)

FL

Foot Locker

$74.23

0.55 (0.75%)

DE

Deere

$101.50

-1.2 (-1.17%)

ARCH

Arch Coal

$79.32

1.6 (2.06%)

ELY

Callaway Golf

$11.68

-0.3 (-2.50%)

GME

GameStop

$24.27

-0.37 (-1.50%)

AEO

American Eagle

$16.17

-0.57 (-3.41%)

JCP

J.C. Penney

$9.81

0.28 (2.94%)

GOOG

Alphabet

$750.50

2.58 (0.34%)

GOOGL

Alphabet Class A

$764.46

0.13 (0.02%)

MRK

Merck

$61.13

0.37 (0.61%)

DIS

Disney

$98.50

-0.44 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 06

    Dec

  • 09

    Jan

  • 15

    Jan

  • 08

    Mar

  • 13

    Mar

TRIP

TripAdvisor

$46.46

-0.7 (-1.48%)

21:40
12/04/16
12/04
21:40
12/04/16
21:40
Upgrade
TripAdvisor rating change  »

TripAdvisor upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTXS

Citrix

$85.62

0.15 (0.18%)

21:40
12/04/16
12/04
21:40
12/04/16
21:40
Upgrade
Citrix rating change  »

Citrix upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 08

    Dec

XOM

Exxon Mobil

$87.04

-0.2 (-0.23%)

21:12
12/04/16
12/04
21:12
12/04/16
21:12
Periodicals
Trump widens Secretary of State search, will interview Exxon Mobil CEO, WSJ says »

President-elect Donald…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

NVS

Novartis

$68.17

0.42 (0.62%)

, JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

21:08
12/04/16
12/04
21:08
12/04/16
21:08
Periodicals
Novartis CEO downplays possibility of Actelion bid, Reuters says »

Asked whether Novartis…

NVS

Novartis

$68.17

0.42 (0.62%)

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PCRFY

Panasonic

$10.58

0.19 (1.83%)

21:05
12/04/16
12/04
21:05
12/04/16
21:05
Periodicals
Panasonic eyes European headlight maker ZKW, Nikkei says »

Panasonic plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$109.90

0.41 (0.37%)

21:03
12/04/16
12/04
21:03
12/04/16
21:03
Hot Stocks
Apple comments on U.S. autonomous cars policy, says 'excited' about potential »

The U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

ETP

Energy Transfer Partners

$34.38

1.16 (3.49%)

20:46
12/04/16
12/04
20:46
12/04/16
20:46
Hot Stocks
Army says will not grant easement for Dakota Access Pipeline »

The Department of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$102.02

2.09 (2.09%)

, PFE

Pfizer

$31.63

0.17 (0.54%)

20:25
12/04/16
12/04
20:25
12/04/16
20:25
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

INCY

Incyte

$102.02

2.09 (2.09%)

PFE

Pfizer

$31.63

0.17 (0.54%)

LLY

Eli Lilly

$67.71

1.74 (2.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

  • 15

    Dec

AGIO

Agios Pharmaceuticals

$56.97

-1.09 (-1.88%)

20:11
12/04/16
12/04
20:11
12/04/16
20:11
Hot Stocks
Agios Pharmaceuticals reports data on AG-348, AG-519 »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

KPTI

Karyopharm

$9.28

0.25 (2.77%)

19:59
12/04/16
12/04
19:59
12/04/16
19:59
Hot Stocks
Karyopharm reports updated Phase 2b STORM data »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ABBV

AbbVie

$59.43

0.27 (0.46%)

19:56
12/04/16
12/04
19:56
12/04/16
19:56
Hot Stocks
AbbVie reports data from two IMBRUVICA combination studies »

AbbVie (ABBV) announced…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ABBV

AbbVie

$59.43

0.27 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

BPMC

Blueprint Medicines

$27.01

-0.99 (-3.54%)

19:50
12/04/16
12/04
19:50
12/04/16
19:50
Hot Stocks
Blueprint Medicines reports Phase 1 BLU-285 data »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

INCY

Incyte

$102.02

2.09 (2.09%)

19:45
12/04/16
12/04
19:45
12/04/16
19:45
Hot Stocks
Incyte reports pooled analysis of five-year Jakafi data »

Incyte announced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

GPRO

GoPro

$9.70

-0.12 (-1.22%)

19:42
12/04/16
12/04
19:42
12/04/16
19:42
Hot Stocks
GoPro releases $299 'Karma Grip' camera stabilizer »

GoPro announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 12

    Dec

KPTI

Karyopharm

$9.28

0.25 (2.77%)

19:37
12/04/16
12/04
19:37
12/04/16
19:37
Hot Stocks
Karyopharm reports data from Phase 2 SAIL study »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

19:32
12/04/16
12/04
19:32
12/04/16
19:32
Hot Stocks
Acetylon reports preclinical ACY-957 data »

Acetylon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

GBT

Global Blood Therapeutics

$19.10

-0.1 (-0.52%)

19:30
12/04/16
12/04
19:30
12/04/16
19:30
Hot Stocks
Global Blood Therapeutics reports Phase 1/2 GBT440 data »

Global Blood Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

  • 14

    Dec

  • 15

    Dec

  • 19

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

19:27
12/04/16
12/04
19:27
12/04/16
19:27
Hot Stocks
Acetylon reports initial Phase 1a/b data for citarinostat in myeloma »

Acetylon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

XLRN

Acceleron

$36.29

1.25 (3.57%)

, CELG

Celgene

$117.63

-1.24 (-1.04%)

19:23
12/04/16
12/04
19:23
12/04/16
19:23
Hot Stocks
Acceleron, Celgene report updated data from Phase 2 luspatercept studies »

Acceleron Pharma (XLRN)…

XLRN

Acceleron

$36.29

1.25 (3.57%)

CELG

Celgene

$117.63

-1.24 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

19:05
12/04/16
12/04
19:05
12/04/16
19:05
Hot Stocks
Alnylam reports Phase 2 data on fitusiran in hemophilia »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$122.96

0.95 (0.78%)

19:01
12/04/16
12/04
19:01
12/04/16
19:01
Hot Stocks
Alexion reports data from Phase 1/2 ALXN1210 study »

Alexion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 14

    Dec

LYV

Live Nation

$27.07

-0.44 (-1.60%)

18:58
12/04/16
12/04
18:58
12/04/16
18:58
Hot Stocks
Live Nation acquires 51% stake in Australia's Secret Sounds Group »

Live Nation Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$68.17

0.42 (0.62%)

18:45
12/04/16
12/04
18:45
12/04/16
18:45
Hot Stocks
Novartis reports Phase 2 data on CTL019 in leukemia »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.